Drug Database
TK

TK-129 (TK 129 / TK129)

✓ Approved

Foshan Rexiu Biotechnology · LRP1

What is TK-129?

TK-129 is a therapeutic agent developed by Foshan Rexiu Biotechnology. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesTK 129, TK129
CompanyFoshan Rexiu Biotechnology
Molecular TargetLRP1
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Foshan Rexiu Biotechnology

Mechanism of Action

Molecular Targets

TK-129 acts on 1 molecular target:

LRP1LDL receptor related protein 1 (LRP1A, A2MR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

TK-129 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Rectosigmoid cancer✓ Approved

Related Research Articles

PubMedAnesthesiology and pain medicine2026-09-20

Enhanced Delivery of Transforaminal Epidural Steroid Injection (TFESI) for Radiculopathy Associated with Acute Lumbar Disc Prolapse Through Physiotherapist-led Assessment, Consent, and Direct Listing.

Mattocks Greta G, Meshykhi Layla L, Thornton Benjamin B, Goebel Andreas A et al.

Invasive treatments for lumbar radiculopathy with persistent symptoms and concordant disc prolapse include a transforaminal epidural steroid injection (TFESI) and microdiscectomy. Evidence supports TFESI as a potential first-line alternative to surgery. Our expedited nerve root block service (ERBS) reduced progression to surgery; however, waiting times remained suboptimal. We evaluated a streamlined pathway incorporating physiotherapy-led consent and direct TFESI listing. This retrospective observational study evaluated a pathway modification in which the pre-procedure specialist consultation was removed. Two Musculoskeletal Clinical Assessment Service (MCAS) physiotherapists were trained to assess suitability, obtain consent, and list patients directly for TFESI, with consultant validation conducted virtually. The primary outcomes were the median waiting time from MCAS consent to TFESI and the change in waiting time compared with the previous pathway. Secondary outcomes were the proportion of listings validated, patient-reported response to TFESI, progression to surgery, and the association between TFESI response and disc pathology. A total of 129 patients provided consent (mean age, 47.3 ± 12.7 years; 95% confidence interval (CI), 45.1 - 49.5; 63.6% female), with 100% validation. The median waiting time from MCAS consent to TFESI was 50 days (range, 2 - 262 days), representing a 37-day reduction (43%) compared with the previous pathway. A positive TFESI response occurred in 83% of patients, and 14% required microdiscectomy. Response rates were similar for disc protrusion (84%) and extrusion (81%). A physiotherapy-led ERBS pathway was associated with reduced waiting times and no identified safety concerns, while maintaining a low conversion rate to surgery.

PMID 42763667
Read full article →
PubMedBJUI compass2026-09-20

The use of biparametric magnetic resonance imaging in active surveillance of prostate cancer.

Rivera López Carlos A CA, Higgins Michelle I MI, Jing Yuezhou Y, Alshak Mark N MN et al.

This study aims to evaluate the performance of biparametric magnetic resonance imaging (bpMRI) compared to multiparametric MRI (mpMRI) for active surveillance (AS) in prostate cancer (PCa), focusing on lesion detection, PI-RADS classification changes and grade reclassification (GR) rates. We retrospectively reviewed our institutional AS database for men who underwent mpMRI followed by bpMRI. Lesion counts and PI-RADS classification were compared. Second, a subgroup of men who underwent mpMRI, biopsy, bpMRI and then repeat biopsy ('bpMRI biopsy group') was matched to a control group who underwent mpMRI, biopsy, another mpMRI and then repeat biopsy ('mpMRI biopsy group') based on age, PSA density, year of diagnosis and number of positive cores. GR rates at systematic and targeted biopsy of all PI-RADS 3-5 lesions were compared, as were PI-RADS changes. A total of 129 men with a median of 29 months between mpMRI and bpMRI were included. mpMRI identified 77 PI-RADS 3-5 lesions versus 114 on subsequent bpMRI (0.60 vs. 0.88 lesions/patient, p = 0.01); however, lesion distribution was similar, with rates of PI-RADS 3, 4 and 5 lesions of 53%, 40% and 6% on mpMRI and 53%, 37% and 11% on subsequent bpMRI (p = 0.87, 0.29 and 0.23, respectively). In the matched biopsy subgroups, when comparing men who had two surveillance mpMRIs with those who had a surveillance mpMRI followed by a surveillance bpMRI, lesion stability was not significantly different across PI-RADS categories. GR at last biopsy occurred in 29% of the bpMRI biopsy group versus in 25% of the mpMRI biopsy group (p = 0.7). bpMRI appears safe to incorporate into AS over the short term, as it was noninferior to mpMRI with similar GR rates and lesion stability.

PMID 42763568
Read full article →
PubMedClinical ophthalmology (Auckland, N.Z.)2026-09-20

Real-World Analysis of Switching Between Ranibizumab Biosimilars: Safety and Results - a Multicenter Retrospective Observational Study.

Chakraborty Debdulal D, Sinha Tushar Kanti TK, Biswas Rupak Kanti RK, Maiti Aniruddha A et al.

To describe disease-specific visual, anatomical, treatment-exposure, and documented safety outcomes over 24 weeks among eyes undergoing availability-driven switching between ranibizumab biosimilars in routine retinal practice in India. This multicenter retrospective observational cohort study reviewed records from January to December 2024. Baseline was the index-switch visit, before administration of the substituted ranibizumab biosimilar. Only one eye per patient was included; when both eyes were eligible, the right eye was selected by convention. Eligible eyes had at least one documented availability-driven biosimilar-to-biosimilar switch and complete 24-week follow-up. Outcomes were summarized descriptively because there was no non-switch comparator group. Of 742 screened eyes, 595 eyes from 595 patients met the inclusion criteria and received 1625 intravitreal ranibizumab biosimilar injections over 24 weeks (mean, 2.73 injections per eye). One switch was recorded in 466 eyes (78.3%) and two switches in 129 eyes (21.7%). Mean BCVA improved from 0.57 logMAR at baseline to 0.26 at 12 weeks and 0.32 at 24 weeks; the early visual improvement therefore attenuated modestly by week 24 but remained better than baseline. Mean central macular thickness decreased from 490.4 micrometers at baseline to 273.6 micrometers at 24 weeks. At final follow-up, 369 eyes (62.0%) gained at least two lines and 488 eyes (82.0%) maintained or improved vision. No endophthalmitis, retinal detachment, or treatment-related systemic adverse event was documented in the available clinical records. Eyes exposed to availability-driven switching between ranibizumab biosimilars showed favorable short-term visual and anatomical outcomes over 24 weeks. Because this retrospective study lacked a non-switch comparator and protocol-mandated safety or immunogenicity surveillance, it cannot establish an effect attributable to switching, comparative safety, equivalence, or formal interchangeability.

PMID 42763736
Read full article →
PubMedSpine deformity2026-09-19

Postoperative thoracic kyphosis morphology following adult spinal deformity surgery: an analysis of fused and unfused segments.

Lafage Renaud R, Elysee Jonathan C JC, Daniels Alan H AH, Diebo Bassel G BG et al.

Predicting post-operative changes in thoracic kyphosis (TK) remains challenging in adult spinal deformity (ASD) surgery. This study aimed to quantify both iatrogenic and reciprocal changes in TK following lumbar correction and assess their maintenance at 2-year follow-up. A retrospective analysis was performed on 356 ASD patients treated with posterior instrumentation from T9-11 to the pelvis, with a minimum 2-year follow-up. TK values were compared with normative data. Multivariate analysis identified thoracolumbar parameters associated with reciprocal thoracic changes and proximal failure. Pre-op TK (median 34°) was normal for 59.8% and hypokyphotic for 39.0% of patients. At 6 weeks, 79.1% of initially hypokyphotic patients normalized, while 11.3% of normokyphotic patients deteriorated. Postoperative TK increase correlated with lumbar lordosis gain (p<0.001), controlling for pre-op alignment and demographics (R2=0.40). Between 6 weeks and 2 years, 9.3% experienced TK decompensation >15°, and 9.6% required proximal extension for junctional issues-defined collectively as "thoracic failures" (17.4%). Independent predictors of failure included advanced age (OR 3.6), more proximal lumbar correction (OR 1.9), and pronounced early mid-thoracic kyphosis (OR 2.3). In ASD surgery with Upper Instrumented Vertebra (UIV) between T9 and T11, changes in TK were largely proportional to lumbar correction, leading to normalization in most cases. However, age, the location of lumbar correction, and early post-operative thoracic shape independently predicted thoracic failure, highlighting the need for tailored alignment strategies.

PMID 42760478
Read full article →
PubMedPain management2026-09-19

Complications of ReActiv8 for chronic low back pain: an analysis of the FDA MAUDE database.

Conic Rosalynn R Z RRZ, Kivanc Tugba T, Fischer Azadeh A, Pasya Sai K SK et al.

Chronic low back pain (CLBP) is a common multifactorial condition associated with- lumbar multifidus dysfunction and impaired neuromuscular control, which ReActiv8 addresses. As its use increases, real-world post-market adverse event data are needed. In this retrospective observational analysis, medical device reports (MDRs) related to ReActiv8 were extracted from the FDA Manufacturer and User Facility Device Experience (MAUDE) database 6/17/2021-12/31/2025 (n = 341). Narrative reports were categorized into procedure-related (e.g. infection, hematoma/seroma, etc.), device-related (e.g. migration, lead damage, hardware malfunction, etc.), or patient-related (e.g. pocket pain, unwanted stimulation) complications after exclusion of duplicate or miscoded events. There were 331 unique MDRs describing 344 reported events. Device-related events represented the largest proportion (n = 174, 50.6%), followed by patient-related (n = 109, 31.7%) and procedure-related events (n = 61, 17.7%). Surgical technique-related factors were reported as a possible contributing factor in 12.69% (n = 42) MDRs. Reported management included revision in 195 (58.91%) and explantation in 129 (38.97%). This characterization of ReActiv8-associated adverse events may help identify areas relevant to patient counseling, surgical technique, and future device optimization; however, these data cannot be used to estimate complication incidence or overall device safety.

PMID 42762487
Read full article →
PubMedFrontiers in plant science2026-09-19

Metatranscriptomic profiling uncovers a distinctive pepper virome in tropical Indonesia.

Suryaningsih Andika Septiana AS, Jang Seok-Yeong SY, Makyorukty Dhayanti D, Byun Hee-Seong HS et al.

Pepper (Capsicum annuum L.) is an important horticultural crop in Indonesia, yet the virome structure of pepper fields in the country remains largely unknown. Here, we used RNA-Seq-based metatranscriptomics to characterize viruses associated with symptomatic pepper plants from six geographically distinct locations in West Java. Six pooled regional libraries were analyzed, resulting in the identification of 129 plant virus-associated contigs. The pepper virome was strongly dominated by cucumber mosaic virus (CMV), while pepper vein yellows virus (PeVYV) and pepper yellow leaf curl Indonesia virus (PYLCIV) were consistently detected across all regions. Several lower-abundance viruses showed regional patterns, including chilli veinal mottle virus, potato virus Y, pepper cryptic virus 2, PeVYV-associated RNA, and tomato yellow leaf curl Kanchanaburi virus. Phylogenetic analyses suggested that CMV in West Java is related to an established Indonesian lineage, whereas PeVYV and PYLCIV populations are genetically structured across regions. In addition, RNA-Seq revealed two previously unrecognized putative virus-associated sequences related to tobacco bushy top virus and grapevine endophyte endornavirus. Because the libraries were generated from pooled samples, read-based values were interpreted as relative viral RNA abundance rather than field incidence. These findings reveal a CMV-dominated but regionally structured pepper virome in West Java and provide a foundation for virus surveillance and disease management in Indonesia.

PMID 42761200
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about TK-129